Ninety-seven percent of hepatitis C patients also infected with HIV were cured of the liver-destroying virus after 12 weeks of treatment with Bristol-Myers Squibb's daclatasvir and Gilead Sciences' Sovaldi, according to data from a study presented. The results could help put Bristol's hepatitis C program back on track in the United States, following a setback last year. Read more here: bit.ly/1DiouoE